Prepared by the Real Experts for the Real World Executives
This annually-updated Guide is the most authoritative and comprehensive reference and resource in English which is instrumental for executives to plan, implement, monitor and supervise pharmaceutical businesses in China.
* Authored by James J. Shen, a veteran pharmaceutical executive and the Publisher and Chief Editor of Pharma China, who has 20 years of managing China and Asian pharmaceutical businesses as a leading China business consultant, multinational company executive and an entrepreneur.
* Prepared by Real Experts for Real World Executives to help them navigate through the complex and turbulent Chinese healthcare business environment for success
* Extensive coverage on China's pharmaceutical industry structure and market environment, regulatory framework, healthcare provision and financing, disease & drug consumption patterns, pharmaceutical sales, marketing & distribution, contemporary trends and opportunities, market entry strategies, case studies of successes and failures in six key areas of the Chinese pharmaceutical business, and profiles of leading MPCs in China.
* Comprehensive data and statistics on the Chinese pharmaceutical industry and market, the Chinese healthcare sector, and disease & drug consumption patterns – much of the data made available exclusively by reputable sources to China Pharmaceutical Guide and Pharma China.
* A complete and clear picture of the Chinese drug regulatory framework is presented with thorough coverage of all regulations in drug registration, research/GLP, clinical/GCP, import and export, manufacture/GMP, packaging, advertising, distribution/GSP, OTC/ethical drug classification, adverse drug reaction monitoring, internet drug sales, physician drug prescription, etc. Summaries of all these regulations are provided with analysis. In addition, a thorough introduction of all drug related government agencies and industry associations is given with their functions analyzed.
* A thorough review of contemporary issues and challenges facing the pharmaceutical industry in China, as well as promising opportunities with many real world examples.
* Market entry strategies are evaluated and analyzed with real world examples.
* Divided into 10 Parts with 52 Chapters, in addition to Preface, Executive Summary and Appendices, it has over 700 pages with more than 100 tables and charts.
* Updated annually to ensure the most up-to-date coverage and trend analysis
* Significantly expanded coverage by the 2007 Edition as follows:
- All industry, market and health sector data are updated with the 2006 (full year) and early 2007 figures
- All regulatory changes updated to present a clear picture of the Chinese drug regulatory framework with summaries and analysis of all drug regulations in effect
- An addition of 8 chapters and near 200 page of new data, information and case studies
- New coverage on the Chinese vaccine sector, the Chinese biopharmaceutical sector, the API/bulk drug sector, and the Chinese private hospital market.
- 11 mini case studies in six important areas including market entry, R&D outsourcing, human resource management, market size/information sources, legal/IPR battles and local success stories.
- Profiles of major multinational pharmaceutical companies operating in China.
* All purchasers of the China Pharmaceutical Guide 2007 edition will receive one-year subscription of Pharma China Weekly e-Alert (Premium Edition) which provides a concise summary of the top Chinese pharmaceutical news in every week.
The ten parts of the Guide is as follows:
Part I - Social, Demographic and Economic Environment - Part I provides a birds-eye-view on China’s economy today covering the country’s demographic trends, its economic infrastructure, contemporary issues and recent trends in foreign investment.
Part II - The Chinese Pharmaceutical Industry and Market - Firstly, Part II of the Guide examines the structure and development of the Chinese pharmaceutical industry, as well as trends of foreign investment in the industry. Secondly, an overview of China's ethical pharmaceutical market and OTC pharmaceutical market is provided. Additional subjects in Part II include intellectual property, and related import tariffs and tax issues.
Part III - Pharmaceutical Regulatory Framework - In Part III, China’s current regulatory structure, important pharmaceutical related laws and regulations, major government agencies and trade associations in the pharmaceutical field are examined and studied in details.
Part IV - Healthcare Provision and Financing – Part IV provides an overview of medical provision and healthcare financing structure, as well as cost containment measures and contemporary issues in healthcare.
Part V - Disease and Drug Consumption Patterns – This Part deals in great details with patterns of popular disease morbidity, hospital visits, and drug consumption at hospital and retail levels. Chinese drug market size and segmentations as well as market shares between multinational and local drug products are analyzed.
Part VI - Pharmaceutical Sales, Marketing and Distribution in China – Part VI covers strategies, practices and current trends of pharmaceutical sales, marketing and distribution in China at hospital and retail levels.
Part VII - Contemporary Issues, Trends, and Opportunities – This Part looks at the current challenges, trends and potential growth opportunities facing the local pharmaceutical industry and multinationals.
Part VIII - Market Entry Strategies and Execution – Part VIII provides practical guides to formulation and implementation of market entry strategies, and advices on potential problems and realities for expatriates and foreign companies operating in China’s complex pharmaceutical market environment.
Part IX - Mini Case Studies - 11 mini case studies in six important areas including market entry, R&D outsourcing, human resource management, market size/information sources, legal/IPR battles and local success stories.
Part X - Company Profiles - Comprehensive profiles and details of 40 leading multinational pharmaceutical companies in China with their latest sales performance data.
Over 750 pages
Published in June 2007
Formats available: Print and PDF
Pricing Information:
|
|
USD |
RMB |
|
Print |
3,800 |
27,800 |
|
Single-user PDF |
3,800 |
27,800 |
|
Site PDF |
11,000 |
78,800 |
|
Global PDF |
22,000 |
156,000 |
For a full table of contents of the Guide or additional information, please contact WiCON International Group via tel: +1 570-588-3854, fax: +1 702-9953905, e-mail: info@pharmachinaonline.com.
To place an order for our publications, please download our product catalog and order form:  Catalog+Order Form+Descriptions-2008.pdf
To download a promotional PDF which contains Executive Summary and Table of Contents, please click: CPG 2007 - TOC+Executive Summary.pdf
|
